Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 5/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15740608 | 0.87 | OGA (0.42) | OGAKDM1AACHEPIK3CDPIK3R1 | |
| SCHEMBL4498299 | 0.81 | OGA (0.38) | OGAKDM1AACHEPTPN11KDM4E | |
| SCHEMBL5458689 | 0.81 | ACHE (0.56) | OGAACHEPTPN11LMNA | |
| SCHEMBL3910163 | 0.79 | MEN1 (0.50) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL4498304 | 0.78 | OGA (0.48) | OGAKDM1AACHEKDM4E | |
| SCHEMBL29958994 | 0.78 | HRH4 (0.56) | OGAACHE | |
| SCHEMBL4948656 | 0.78 | HRH4 (0.56) | OGAACHE | |
| SCHEMBL10187275 | 0.76 | KDM1A (0.48) | OGAKDM1AACHEPIK3CDPIK3R1 | |
| SCHEMBL4947574 | 0.76 | KDM1A (0.48) | OGAKDM1AACHEPIK3CDPIK3R1 | |
| SCHEMBL5452260 | 0.75 | GRIN2D (0.46) | MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | OGA 1681/4885KDM1A 1449/4885ACHE 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.